Drug Profile
Decorin
Alternative Names: Recombinant human decorinLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator The Burnham Institute
- Developer Telios Pharmaceuticals
- Class Antihyperglycaemics; Hepatoprotectants
- Mechanism of Action Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Diabetic nephropathies; Inflammation; Post-surgical adhesions; Pulmonary fibrosis; Spinal cord injuries